Background Most patients with biliary tract cancer (BTC) do not derive durable clinical benefit (DCB) from immune checkpoint inhibitors (ICIs), underscoring the urgent need for predictive biomarkers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results